Nanobiotix’s (NBTX) “Buy” Rating Reiterated at Guggenheim

Nanobiotix (NASDAQ:NBTX)‘s stock had its “buy” rating reissued by research analysts at Guggenheim in a research report issued on Tuesday, Benzinga reports. They presently have a $64.00 price target on the stock. Guggenheim’s target price points to a potential upside of 79.12% from the company’s current price.

Several other equities analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Finally, Leerink Partners raised their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, June 4th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.

Nanobiotix Stock Down 3.5%

NASDAQ NBTX opened at $35.73 on Tuesday. Nanobiotix has a 1-year low of $9.32 and a 1-year high of $57.14. The stock’s 50 day moving average is $39.58 and its two-hundred day moving average is $37.20.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.